Correlation Between Day One and Immatics Biotechnologies
Can any of the company-specific risk be diversified away by investing in both Day One and Immatics Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Day One and Immatics Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Day One Biopharmaceuticals and immatics biotechnologies GmbH, you can compare the effects of market volatilities on Day One and Immatics Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Day One with a short position of Immatics Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Day One and Immatics Biotechnologies.
Diversification Opportunities for Day One and Immatics Biotechnologies
0.06 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Day and Immatics is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Day One Biopharmaceuticals and immatics biotechnologies GmbH in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immatics Biotechnologies and Day One is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Day One Biopharmaceuticals are associated (or correlated) with Immatics Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immatics Biotechnologies has no effect on the direction of Day One i.e., Day One and Immatics Biotechnologies go up and down completely randomly.
Pair Corralation between Day One and Immatics Biotechnologies
Given the investment horizon of 90 days Day One Biopharmaceuticals is expected to generate 0.21 times more return on investment than Immatics Biotechnologies. However, Day One Biopharmaceuticals is 4.78 times less risky than Immatics Biotechnologies. It trades about -0.05 of its potential returns per unit of risk. immatics biotechnologies GmbH is currently generating about -0.29 per unit of risk. If you would invest 1,413 in Day One Biopharmaceuticals on September 13, 2024 and sell it today you would lose (132.00) from holding Day One Biopharmaceuticals or give up 9.34% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 89.06% |
Values | Daily Returns |
Day One Biopharmaceuticals vs. immatics biotechnologies GmbH
Performance |
Timeline |
Day One Biopharmaceu |
Immatics Biotechnologies |
Day One and Immatics Biotechnologies Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Day One and Immatics Biotechnologies
The main advantage of trading using opposite Day One and Immatics Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Day One position performs unexpectedly, Immatics Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immatics Biotechnologies will offset losses from the drop in Immatics Biotechnologies' long position.Day One vs. X4 Pharmaceuticals | Day One vs. Inozyme Pharma | Day One vs. Acumen Pharmaceuticals | Day One vs. Mereo BioPharma Group |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Complementary Tools
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |